Available and affordable complementary treatments for COVID-19: From hypothesis to pilot studies and the need for implementation
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Bousquet, Jean
- dc.contributor.author Haahtela, Tari
- dc.contributor.author Blain, Hubert
- dc.contributor.author Czarlewski, Wienczyslawa
- dc.contributor.author Zuberbier, Torsten
- dc.contributor.author Bedbrook, Anna
- dc.contributor.author Cruz, Alvaro A.
- dc.contributor.author Fonseca, Joao A.
- dc.contributor.author Klimek, Ludger
- dc.contributor.author Kuna, Piotr
- dc.contributor.author Samolinski, Boleslaw
- dc.contributor.author Valiulis, Arunas
- dc.contributor.author Lemaire, Antoine
- dc.contributor.author Antó i Boqué, Josep Maria
- dc.date.accessioned 2022-05-02T06:08:37Z
- dc.date.available 2022-05-02T06:08:37Z
- dc.date.issued 2022
- dc.description.abstract Vaccination is a highly effective preventive measure against COVID-19. However, complementary treatments are needed to better control the disease. Fermented vegetables and spices, agonists of the antioxidant transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and TRPA1/V1 channels (Transient Receptor Potential Ankyrin 1 and Vanillin 1), may help in the control of COVID-19. Some preliminary clinical trials suggest that curcumin (spice) can prevent some of the COVID-19 symptoms. Before any conclusion can be drawn and these treatments recommended for COVID-19, the data warrant confirmation. In particular, the benefits of the foods need to be assessed in more patients, through research studies and large trials employing a double-blind, placebo-controlled design.
- dc.format.mimetype application/pdf
- dc.identifier.citation Bousquet J, Haahtela T, Blain H, Czarlewski W, Zuberbier T, Bedbrook A, Cruz AA, Fonseca JA, Klimek L, Kuna P, Samolinski B, Valiulis A, Lemaire A, Anto JM. Available and affordable complementary treatments for COVID-19: From hypothesis to pilot studies and the need for implementation. Clin Transl Allergy. 2022 Mar;12(3):e12127. DOI: 10.1002/clt2.12127
- dc.identifier.doi http://dx.doi.org/10.1002/clt2.12127
- dc.identifier.issn 2045-7022
- dc.identifier.uri http://hdl.handle.net/10230/52951
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Clin Transl Allergy. 2022 Mar;12(3):e12127
- dc.rights © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword COVID-19
- dc.subject.keyword Nrf2
- dc.subject.keyword TRP channel
- dc.subject.keyword Broccoli
- dc.subject.keyword Curcumin
- dc.title Available and affordable complementary treatments for COVID-19: From hypothesis to pilot studies and the need for implementation
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion